What happened?

BioCryst Pharmaceuticals (NASDAQ:BCRX) stock is dropping sharply on Thursday after the biotech company reported disappointing fourth-quarter financial results. BioCryst's shares were down by 8.4% as of 1:53 p.m. EST. 

So what

BioCryst's total revenue for the fourth quarter ending Dec. 31 was roughly $4 million, down from the $39.7 million in revenue recorded during the year-ago period. In the fourth quarter of 2019, the company recognized a one-time revenue of $20.1 million, and it also reported $13.9 million in revenue from the sale of flu medicine Rapivab under a contract with the U.S. Department of Health and Human Services. During Q4 2020, BioCryst did not record any sales from Rapivab; these factors help explain the year-over-year decrease in the company's top line. 

Down-trending arrows on a blackboard

Image source: Getty Images.

Still, the biotech's revenue came in well short of the $14.74 million consensus analyst estimate. On the bottom line, BioCryst recorded a net loss of $60.5 million and a net loss per share of $0.34. During Q4 2019, the company reported a net loss of $2.6 million -- or $0.02 on a per-share basis. The consensus estimate for the company's bottom line was a net loss of $0.25. For the full fiscal year 2020, BioCryst posted total revenue of $17.8 million and a net loss per share of $1.09. Those metrics were below the $28.2 million in revenue and the $1 loss per share analysts expected.

Now what

Despite BioCryst's disappointing fourth-quarter financial results, investors have something to look forward to with this healthcare stock. Back in December, the U.S. Food and Drug Administration approved the company's Orladeyo, a once-daily pill to prevent hereditary angioedema attacks. The company expects this medicine to rack up global peak sales of more than half a million dollars. Thanks to Orladeyo, BioCryst's financial results could look much better this year than they did last year. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.